Tuesday, 04 September 2012The allocation
of shares in Swedbank AB (”Swedbank”) has changed due to owners of
preference shares having requested during the month of August, 2012
conversion of an aggregate of 8,266,802 preference shares into ordinary
shares pursuant to the conversion clause set forth in Swedbank’s
articles of association.

Tuesday, 04 September 2012From 1st of
January 2013 H&M Group puts a global ban on Perfluorinated
Compounds (PFC:s). This means that all orders placed 1st of January
2013 or later will be produced without PFC:s.

Thursday, 30
August 2012Elekta has won
a major contract related to the development of cancer treatment in the
Chinese Army, People's Liberation Army, which operates the Army's
military hospital.Diamyd Medical reports results from
Phase II study in cancer painTuesday, 03
July 2012Diamyd Medical
AB reports that a Phase II study evaluating the Company’s drug
candidate NP2 Enkephalin did not meet its primary objective of reducing
pain in subjects with severe intractable cancer pain. The treatment was
however well tolerated, confirming the safety of the Company’s NTDDS
technology.

Monday, 25 June
2012The Committee
for Human Medicinal Products (CHMP) of the European Medicines Agency
(EMA) has adopted a positive opinion regarding marketing authorization
of Zyclara (treatment of actinic keratoses on large skin areas).

Friday, 01 June
2012Alfa
Laval has won an order from a Technip Samsung Consortium (TSC) to
supply Alfa Laval equipment to Shell’s Prelude FLNG (floating liquefied
natural gas) facility. Alfa Laval is unable to disclose the exact value
of the order due to a confidentiality agreement.